X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 58 filers reported holding X4 PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,202 | -0.8% | 10,277 | +76.6% | 0.00% | – |
| Q2 2023 | $11,293 | +1129200.0% | 5,821 | +618.6% | 0.00% | – |
| Q1 2023 | $1 | -90.0% | 810 | -92.1% | 0.00% | – |
| Q4 2022 | $10 | -99.8% | 10,227 | +81.4% | 0.00% | – |
| Q2 2022 | $5,000 | -68.8% | 5,639 | -41.8% | 0.00% | – |
| Q1 2022 | $16,000 | +128.6% | 9,695 | +675.6% | 0.00% | – |
| Q3 2021 | $7,000 | -91.9% | 1,250 | -90.6% | 0.00% | -100.0% |
| Q2 2021 | $86,000 | +230.8% | 13,231 | +337.7% | 0.00% | – |
| Q1 2021 | $26,000 | -33.3% | 3,023 | -50.6% | 0.00% | -100.0% |
| Q4 2020 | $39,000 | -67.2% | 6,124 | -65.2% | 0.00% | 0.0% |
| Q3 2020 | $119,000 | +310.3% | 17,588 | +470.7% | 0.00% | 0.0% |
| Q2 2020 | $29,000 | -3.3% | 3,082 | +54.6% | 0.00% | -50.0% |
| Q2 2019 | $30,000 | +275.0% | 1,994 | +343.1% | 0.00% | – |
| Q1 2019 | $8,000 | – | 450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 1,717,589 | $3,006,000 | 1.17% |
| SV Health Investors, LLC | 311,490 | $545,000 | 0.66% |
| Bain Capital Life Sciences Investors, LLC | 3,019,540 | $5,284,000 | 0.51% |
| AIGH Capital Management LLC | 997,719 | $1,746,000 | 0.43% |
| Ikarian Capital, LLC | 1,372,022 | $2,402,000 | 0.32% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $586,000 | 0.29% |
| Worth Venture Partners, LLC | 250,144 | $438,000 | 0.20% |
| Sio Capital Management, LLC | 276,909 | $485,000 | 0.16% |
| BVF INC/IL | 847,879 | $1,484,000 | 0.06% |
| Orbimed Advisors | 1,373,849 | $2,404,000 | 0.04% |